Analysts Set Expectations for Edesa Biotech FY2029 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – Research analysts at Brookline Capital Markets issued their FY2029 earnings per share estimates for shares of Edesa Biotech in a research note issued to investors on Monday, June 29th. Brookline Capital Markets analyst K. Raja anticipates that the company will post earnings per share of ($1.87) for the year. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.57) per share. Brookline Capital Markets also issued estimates for Edesa Biotech’s FY2030 earnings at ($0.83) EPS.

Edesa Biotech (NASDAQ:EDSA) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.25).

EDSA has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Edesa Biotech in a research report on Wednesday, June 24th. Wall Street Zen upgraded Edesa Biotech from a “strong sell” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.00.

Edesa Biotech Stock Performance

EDSA opened at $8.13 on Wednesday. The stock has a fifty day moving average of $9.49 and a 200-day moving average of $5.34. Edesa Biotech has a fifty-two week low of $0.72 and a fifty-two week high of $20.32. The company has a market capitalization of $72.28 million, a P/E ratio of -6.07 and a beta of 1.03.

Hedge Funds Weigh In On Edesa Biotech

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp acquired a new position in shares of Edesa Biotech in the 4th quarter valued at about $27,000. Susquehanna International Group LLP acquired a new position in shares of Edesa Biotech during the third quarter valued at about $36,000. Diadema Partners LP acquired a new position in Edesa Biotech during the 4th quarter valued at about $77,000. DRW Securities LLC purchased a new position in shares of Edesa Biotech during the fourth quarter valued at approximately $191,000. Finally, Perceptive Advisors LLC purchased a new position in Edesa Biotech during the first quarter worth about $2,946,000. 5.50% of the stock is owned by institutional investors and hedge funds.

About Edesa Biotech

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.